CNTFR Gene

CNTFR Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CNTFR Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CNTFR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ciliary Neurotrophic Factor Receptor Alpha</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1271</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000122756</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P26992</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>118400</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Recombinant CNTF</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">CNTFR-Fc fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">AAV-CNTR gene therapy</td>
<td>Development</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">R228C</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">P406L</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Splice variants</td>
<td>Alternative splicing</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Role</td>
</tr>
<tr>
<td class="label">CNTFRα</td>
<td>Ligand-binding subunit</td>
</tr>

CNTFR Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CNTFR Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CNTFR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ciliary Neurotrophic Factor Receptor Alpha</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1271</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000122756</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P26992</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>118400</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Recombinant CNTF</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">CNTFR-Fc fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">AAV-CNTR gene therapy</td>
<td>Development</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">R228C</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">P406L</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Splice variants</td>
<td>Alternative splicing</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Role</td>
</tr>
<tr>
<td class="label">CNTFRα</td>
<td>Ligand-binding subunit</td>
</tr>
<tr>
<td class="label">GP130</td>
<td>Signal-transducing subunit[@liu2023]</td>
</tr>
<tr>
<td class="label">LIFRβ</td>
<td>Co-receptor subunit</td>
</tr>
<tr>
<td class="label">Species</td>
<td>CNTFR</td>
</tr>
<tr>
<td class="label">Human</td>
<td>CNTFRα</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Cntfrα</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Cntfrα</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>cntfr</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>DCNTFR</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ALS (1990s)</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">Huntington's</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

The CNTFR gene (Ciliary Neurotrophic Factor Receptor Alpha) encodes the alpha subunit of the CNTFR receptor complex, a critical component for CNTF-mediated signaling in the nervous system. CNTFRα is the high-affinity binding component that initiates CNTF signaling, which is essential for neuronal survival, differentiation, and function. The receptor is expressed throughout the central and peripheral nervous system and has significant implications for neurodegenerative disease research and therapy[@benhamou2023].

Gene Overview

Gene and Protein Structure

Chromosomal Organization

The CNTFR gene is located on chromosome 9p13.2 and spans approximately 22 kb of genomic DNA. The gene consists of 8 exons encoding a protein of 400 amino acids with a molecular weight of approximately 45 kDa[@chen2022].

Protein Domain Architecture

The CNTFRα protein is a member of the cytokine receptor family:

• Extracellular cytokine-binding domain (CBD): Contains approximately 300 amino acids with fibronectin type III repeats
• N-terminal signal peptide: Targets protein for secretion
• GPI anchor sequence: C-terminal signal for membrane attachment
• Multiple N-linked glycosylation sites: Important for protein folding and stability

Splice Variants

Multiple CNTFR splice variants have been identified[@park2024]:

• Full-length membrane-bound: Primary functional variant
• Soluble CNTFR: Lacks GPI anchor, circulates as a decoy receptor
• Alternative splicing: Produces variants with altered ligand binding

Protein Product and Receptor Complex

The CNTFRα protein is a glycosylphosphatidylinositol (GPI)-anchored protein that serves as the ligand-binding component of the CNTF receptor complex. It lacks a transmembrane domain and is attached to the cell membrane via a GPI anchor. Together with GP130 and LIFRβ, it forms the functional signaling receptor for CNTF and related cytokines[@chen2022].

Receptor Complex Formation

Function

CNTFRα mediates essential biological functions[@engeland2023]:

Signaling Mechanisms

• JAK/STAT Pathway: Primary CNTF signaling[@nakamura2023]
• STAT3 Activation: Main transcription factor
• MAPK Pathway: Secondary signaling
• PI3K/Akt Pathway: Pro-survival signaling

Expression Pattern

CNTFR is widely expressed in the nervous system[@benhamou2023]:

• Brain: Cortex, hippocampus, cerebellum, basal ganglia
• Spinal cord: Motor neurons, interneurons
• Peripheral nervous system: Sensory neurons, Schwann cells
• Astrocytes: Modulates neuroinflammation
• Neural stem cells: Regulates differentiation[@kim2023]

Role in Neurodegeneration

Alzheimer's Disease

CNTFR has significant implications in AD[@huang2022][@wang2023]:

• CNTF/CNTFR signaling is altered in AD brains: Reduced expression observed in hippocampal and cortical regions
• Protection against amyloid-beta toxicity: CNTF activation prevents neuronal apoptosis through activation of anti-apoptotic proteins
• The pathway may be impaired in AD: Contributes to disease progression through loss of neurotrophic support
• Therapeutic potential: CNTFR agonists may restore neuroprotective signaling in AD patients
• Synaptic function: CNTFR signaling supports synaptic plasticity and memory formation
• Neuroinflammation modulation: The pathway regulates astrocyte-mediated inflammatory responses

Parkinson's Disease

The receptor is highly relevant to PD[@yang2022][@gao2023]:

• Expressed in dopaminergic neurons: High levels in substantia nigra pars compacta
• CNTF can protect substantia nigra neurons: Prevents dopaminergic cell death in toxin-based models
• Gene therapy approaches: AAV-mediated CNTFR expression in development for sustained delivery
• Enhances dopamine neuron survival: Through JAK-STAT signaling and anti-apoptotic mechanisms
• Mitochondrial protection: CNTFR activation preserves mitochondrial function in dopaminergic neurons
• Motor behavior improvement: CNTF treatment improves motor function in PD animal models

Motor Neuron Disease (ALS)

CNTFR is essential for motor neuron function[@liu2023][@tateishi2022]:

• Motor neurons express high CNTFR levels: Critical for survival
• CNTF delivery tested in ALS: Clinical trials conducted
• AAV-mediated CNTFR overexpression: Shows promise in mouse models
• Gene therapy approaches: Target the receptor for treatment

Neuroinflammatory Conditions

CNTFR modulates neuroinflammation through[@singh2023]:

• Astrocyte reactivity: Regulates inflammatory responses
• Microglial activation: Modulates CNS immune status
• Cytokine production: Controls pro-inflammatory mediator release

Therapeutic Targeting

Current Approaches

Agonists and Modulators

• CNTFR-Fc: Soluble receptor fusion proteins with enhanced stability
• Modified CNTF variants: Engineered for reduced side effects
• Small molecule agonists: In development

Gene Therapy Progress

Recent advances in gene therapy have improved CNTF/CNTFR delivery[@muller2022][@gao2023]:

• AAV vectors: Efficient CNS transduction
• Targeted delivery: Intrathecal or stereotactic injection
• Controlled expression: Regulated promoters
• Primate studies: Safety and efficacy demonstrated[@xu2024]

Clinical Considerations

• Side effects limit systemic CNTF use
• Intrathecal delivery being explored
• Biomarkers for patient selection needed
• Combination approaches considered

Genetic Associations

Disease-Associated Variants

CNTFR polymorphisms have been associated with multiple conditions[@davis2024]:

• ALS risk: Specific variants modify disease susceptibility
• Neurological disease: Altered signaling in various disorders
• Pharmacogenomics: Genetic variants affect CNTF therapy response

Functional Variants

Biomarker Potential

Soluble CNTFR has emerged as a potential biomarker for neurodegeneration[@iwata2024]:

• Detection in cerebrospinal fluid: Correlates with disease stage
• Blood-brain barrier integrity: Measures vascular health
• Therapeutic monitoring: Tracks treatment response

Interactions and Signaling Network

Receptor Complex

Downstream Pathways

• JAK/STAT signaling (primary)
• MAPK/ERK pathway
• PI3K/Akt pathway
• Notch signaling crosstalk[@zhang2023]

Research Directions

Current Focus

Unresolved Questions

• What determines optimal CNTF dosing?
• Can early intervention prevent neurodegeneration?
• What is the long-term safety of gene therapy?
• How do CNTFR genetic variants affect treatment response?
• What is the optimal delivery route for maximum CNS exposure?

Emerging Research Areas

• CNTFR splice variant biology: Understanding functional differences between variants[@park2024]
• Notch pathway crosstalk: Exploiting interactions between CNTFR and Notch signaling[@zhang2023]
• Astrocyte-mediated effects: Leveraging astrocyte CNTFR for neuroprotection[@singh2023]
• Biomarker validation: Large-scale validation of soluble CNTFR in clinical cohorts[@iwata2024]

Future Therapeutic Directions

• Engineered CNTFR agonists: Designer proteins with improved properties
• Cell-penetrating peptides: Intracellular delivery of neurotrophic signals
• Combination approaches: CNTFR with disease-modifying agents
• Personalized medicine: Genetic profiling for treatment selection

Receptor Activation Mechanisms

Ligand Binding Dynamics

CNTFRα demonstrates sophisticated ligand binding characteristics:

CNTF Binding:

• High-affinity binding (Kd ~ 10-50 pM)
• Induces receptor complex trimerization
• Glycosylation-dependent interaction
• Soluble CNTFR can act as a decoy

Signal Amplification

The CNTFR signaling cascade demonstrates remarkable amplification:

• Single CNTF molecule → receptor complex → multiple JAK molecules
• JAKs activate numerous STAT3 molecules
• Each p-STAT3 dimer can drive transcription of multiple target genes
• Signal can amplify 10,000-fold from ligand to transcriptional response

Evolutionary Conservation

CNTFR and related receptors show evolutionary conservation:

The conservation across species underscores the fundamental importance of CNTFR-mediated signaling in nervous system function.

Structural Biology

CNTFRα Domain Architecture

The extracellular domain of CNTFRα contains several critical structural elements:

N-terminal cytokine-binding domain (CBD):

• Ig-like fold with conserved disulfide bonds
• Four conserved cysteine residues forming two disulfide bonds
• Ligand-binding interface concentrated in this region
• Contains the WSXWS motif characteristic of cytokine receptors

• Three FNIII domains
• Provide structural rigidity
• Serve as spacer between CBD and GPI anchor
• Important for correct orientation of the CBD

• C-terminal hydrophobic sequence
• Directs protein to cell membrane via GPI modification
• Enables clustering and signal amplification

Ligand-Receptor Interaction

The CNTF-CNTFR interaction has been characterized structurally:

• Binding interface: Extensive contact surface between CNTF and CNTFRα
• Affinities: CNTFRα binding (Kd ~ 1 nM), full complex (Kd ~ 50 pM)
• Cooperativity: Binding shows positive cooperativity for dimer formation
• Allosteric effects: Ligand binding triggers conformational changes

Clinical Trial Status

Historical Trials

CNTF has undergone clinical testing:

Current Developments

Recent progress includes:

• AAV-CNTF delivery in animal models
• CNTFR-Fc fusion proteins in development
• Intrathecal delivery approaches
• Biomarker-driven patient selection

See Also

• [CNTFR Protein](/proteins/cntfr-protein)
• [Ciliary Neurotrophic Factor (CNTF)](/proteins/cntf-protein)
• [JAK-STAT Signaling](/mechanisms/jak-stat-signaling)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [Motor Neuron Disease](/diseases/motor-neuron-disease)

External Links

• [NCBI Gene: CNTFR](https://www.ncbi.nlm.nih.gov/gene/1271)
• [UniProt: CNTFR](https://www.uniprot.org/uniprot/P26992)
• [Ensembl: CNTFR](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122756)
• [OMIM: CNTFR](https://omim.org/entry/118400)
• [Allen Brain Atlas: CNTFR](https://human.brain-map.org/microarray/search/show?search_term=CNTFR)